Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Voyager Therapeutics (VYGR) over the last 11 years, with Q3 2025 value amounting to $45.1 million.

  • Voyager Therapeutics' Cash & Equivalents fell 5989.78% to $45.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.1 million, marking a year-over-year decrease of 5989.78%. This contributed to the annual value of $71.4 million for FY2024, which is 372.81% up from last year.
  • According to the latest figures from Q3 2025, Voyager Therapeutics' Cash & Equivalents is $45.1 million, which was down 5989.78% from $43.9 million recorded in Q2 2025.
  • Over the past 5 years, Voyager Therapeutics' Cash & Equivalents peaked at $268.3 million during Q1 2023, and registered a low of $43.9 million during Q2 2025.
  • Moreover, its 5-year median value for Cash & Equivalents was $99.0 million (2022), whereas its average is $109.7 million.
  • Per our database at Business Quant, Voyager Therapeutics' Cash & Equivalents skyrocketed by 21188.07% in 2023 and then plummeted by 6883.78% in 2024.
  • Voyager Therapeutics' Cash & Equivalents (Quarter) stood at $117.4 million in 2021, then fell by 15.73% to $99.0 million in 2022, then crashed by 30.47% to $68.8 million in 2023, then grew by 3.73% to $71.4 million in 2024, then crashed by 36.77% to $45.1 million in 2025.
  • Its Cash & Equivalents was $45.1 million in Q3 2025, compared to $43.9 million in Q2 2025 and $74.8 million in Q1 2025.